Monica G Valero1, Shirin Muhsen1, Tracy-Ann Moo1, Emily C Zabor2, Michelle Stempel1, Andrea Pusic3, Mary L Gemignani1, Monica Morrow1, Virgilio S Sacchini4. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. sacchinv@mskcc.org.
Abstract
BACKGROUND: Nipple-sparing mastectomy (NSM) is increasingly performed for invasive breast cancer. Growing evidence supporting the oncologic safety of NSM has led to its widespread use and broadened indications. In this study, we examine the indications, complications, and long-term outcomes of therapeutic NSM. METHODS: From 2003 to 2016, women undergoing NSM for invasive cancer or ductal carcinoma in situ (DCIS) were identified from a prospectively maintained database. Patient and disease characteristics were compared by procedure year, while complications were compared by procedure year using generalized mixed-effects models accounting for a random surgeon effect. Overall survival and time to recurrence were examined. RESULTS: Of the 467 therapeutic NSMs, 337 (72%) were invasive cancer, 126 (27%) were DCIS, and 4 (1%) were phyllodes tumors. Median age was 45 years (range 24-75) and median follow-up among survivors was 39.4 months. Three hundred and fifty-seven (76.4%) cases were performed in 2011 or after. When comparing NSMs performed before and after 2011, there was a significant increase in NSMs performed for invasive tumors (58% vs. 77%; p < 0.001). There was no difference in family history, genetic mutations, smoking status, neoadjuvant chemotherapy, prior radiation, nodal involvement, or tumor subtype. Twenty-one (4.5%) nipple excisions were performed, of which 14 were performed for cancer at the nipple margin. Forty-four breasts (9.4%) had complications that required re-operation. Fifteen patients had locoregional recurrence or distant metastasis. CONCLUSIONS: NSM use for invasive carcinoma has doubled at our institution since 2011, while postoperative complications and recurrence rates remain low. Our experience supports the selective use of NSM in the malignant setting with careful patient selection.
BACKGROUND: Nipple-sparing mastectomy (NSM) is increasingly performed for invasive breast cancer. Growing evidence supporting the oncologic safety of NSM has led to its widespread use and broadened indications. In this study, we examine the indications, complications, and long-term outcomes of therapeutic NSM. METHODS: From 2003 to 2016, women undergoing NSM for invasive cancer or ductal carcinoma in situ (DCIS) were identified from a prospectively maintained database. Patient and disease characteristics were compared by procedure year, while complications were compared by procedure year using generalized mixed-effects models accounting for a random surgeon effect. Overall survival and time to recurrence were examined. RESULTS: Of the 467 therapeutic NSMs, 337 (72%) were invasive cancer, 126 (27%) were DCIS, and 4 (1%) were phyllodestumors. Median age was 45 years (range 24-75) and median follow-up among survivors was 39.4 months. Three hundred and fifty-seven (76.4%) cases were performed in 2011 or after. When comparing NSMs performed before and after 2011, there was a significant increase in NSMs performed for invasive tumors (58% vs. 77%; p < 0.001). There was no difference in family history, genetic mutations, smoking status, neoadjuvant chemotherapy, prior radiation, nodal involvement, or tumor subtype. Twenty-one (4.5%) nipple excisions were performed, of which 14 were performed for cancer at the nipple margin. Forty-four breasts (9.4%) had complications that required re-operation. Fifteen patients had locoregional recurrence or distant metastasis. CONCLUSIONS: NSM use for invasive carcinoma has doubled at our institution since 2011, while postoperative complications and recurrence rates remain low. Our experience supports the selective use of NSM in the malignant setting with careful patient selection.
Authors: S S Kroll; A Khoo; S E Singletary; F C Ames; B G Wang; G P Reece; M J Miller; G R Evans; G L Robb Journal: Plast Reconstr Surg Date: 1999-08 Impact factor: 4.730
Authors: Grant W Carlson; Toncred M Styblo; Robert H Lyles; Glyn Jones; Douglas R Murray; Charles A Staley; William C Wood Journal: Surg Oncol Date: 2003-12 Impact factor: 3.279
Authors: Sophocles Lanitis; Paris P Tekkis; George Sgourakis; Nikitas Dimopoulos; Ragheed Al Mufti; Dimitri J Hadjiminas Journal: Ann Surg Date: 2010-04 Impact factor: 12.969
Authors: Lesly A Dossett; Janell Lowe; Weihong Sun; M C Lee; Paul D Smith; Paul B Jacobsen; Christine Laronga Journal: J Surg Oncol Date: 2016-04-18 Impact factor: 3.454
Authors: J Y Petit; U Veronesi; R Orecchia; G Curigliano; P C Rey; E Botteri; N Rotmensz; V Lohsiriwat; M Cassilha Kneubil; M Rietjens Journal: Ann Oncol Date: 2012-01-09 Impact factor: 32.976
Authors: Rong Tang; Suzanne B Coopey; Amy S Colwell; Michelle C Specht; Michele A Gadd; Kari Kansal; Maureen P McEvoy; Andrea L Merrill; Upahvan Rai; Alphonse Taghian; William G Austen; Barbara L Smith Journal: Ann Surg Oncol Date: 2015-07-23 Impact factor: 5.344
Authors: Janet H Yueh; Mary Jane Houlihan; Sumner A Slavin; Bernard T Lee; Susan E Pories; Donald J Morris Journal: Ann Plast Surg Date: 2009-05 Impact factor: 1.539
Authors: L A Newman; H M Kuerer; K K Hunt; S S Kroll; F C Ames; M I Ross; B W Feig; S E Singletary Journal: Ann Surg Oncol Date: 1998 Oct-Nov Impact factor: 5.344
Authors: Suzanne B Coopey; Rong Tang; Lan Lei; Phoebe E Freer; Kari Kansal; Amy S Colwell; Michele A Gadd; Michelle C Specht; William G Austen; Barbara L Smith Journal: Ann Surg Oncol Date: 2013-08-22 Impact factor: 5.344
Authors: Antonio J Esgueva; Iris Noordhoek; Elma Meershoek-Klein Kranenbarg; Martin Espinosa-Bravo; Zoltán Mátrai; Andrii Zhygulin; Arvids Irmejs; Carlos Mavioso; Francesco Meani; Eduardo González; Murat Özdemir; Tanir Allweis; Karol Rogowski; Catarina Rodrigues Dos Santos; Henrique Mora; Riccardo Ponzone; Domenico Samorani; Cornelis van de Velde; Riccardo A Audisio; Isabel T Rubio Journal: Ann Surg Oncol Date: 2021-11-08 Impact factor: 5.344
Authors: Tracy-Ann Moo; Carolina Rossi Saccarelli; Elizabeth J Sutton; Varadan Sevilimedu; Kate R Pawloski; Timothy M D'Alfonso; Mary C Hughes; Jill S Gluskin; Almir Bitencourt; Elizabeth A Morris; Audree Tadros; Monica Morrow; Mary L Gemignani; Virgilio Sacchini Journal: Ann Surg Oncol Date: 2021-04-17 Impact factor: 4.339
Authors: Jiae Moon; Jeea Lee; Dong Won Lee; Hye Sun Lee; Da Jung Nam; Min Jung Kim; Na Young Kim; Hyung Seok Park Journal: Int J Med Sci Date: 2021-04-17 Impact factor: 3.738
Authors: Vincent C Caronna; Allison F Rosenberg; David M Graham; William M Heim; Brooke F Grasperge; Scott K Sullivan; Abigail E Chaffin; Bruce A Bunnell; Nicholas C Pashos Journal: Sci Rep Date: 2021-07-23 Impact factor: 4.379